Nelson N. Stone, MD, presented “Radiation Dose and Hormone Therapy: How Much is Enough?” during the 27th Annual Southwest Prostate Cancer Symposium conference on October 17, 2024, in Scottsdale, Arizona.
How to cite: Stone, Nelson N. “Radiation Dose and Hormone Therapy: How Much is Enough?.” October 17, 2024. Accessed Feb 2025. https://grandroundsinurology.com/radiation-dose-and-hormone-therapy-how-much-is-enough/
Radiation Dose and Hormone Therapy: How Much is Enough? – Summary
Nelson N. Stone, MD, explores the balance between radiation dose and hormonal therapy in managing intermediate- and high-risk prostate cancer. In this 21-minute presentation, Dr. Stone examines how raising radiation doses impacts the need for hormonal therapy, emphasizing the critical role of biological effective dose (BED) calculations in comparing treatment modalities.
Dr. Stone reviews long- and short-term androgen deprivation therapy (ADT) outcomes alongside testosterone recovery, highlighting patient trade-offs. He shares findings from the TRIP study, demonstrating that achieving a BED of at least 200 gray can eliminate the need for extended hormonal therapy without compromising treatment outcomes.
Dr. Stone advocates incorporating patient factors like age, BMI, and baseline testosterone levels into treatment discussions, emphasizing the need for personalized treatment planning, where optimizing radiation dose can reduce hormonal therapy duration and enhance patient quality of life.
About the 27th Annual Southwest Prostate Cancer Symposium:
Presented by Program Chairs Nelson N. Stone, MD, Richard G. Stock, MD, and William K. Oh, MD, this conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Nelson N. Stone, MD, is Professor of Urology, Radiation Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and chief medical officer at Viomerse, Inc.
Dr. Stone earned his medical degree from the University of Maryland in 1979. He completed a Residency in General Surgery in 1981 at the University of Maryland, followed by a Residency in Urology at the University of Maryland. He then completed a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center and a Research Fellowship in Biochemical Endocrinology at Rockefeller University in 1986. He was Chief of Urology at Elmhurst Hospital Queens from 1986-1996.
Dr. Stone has founded several medical companies and serves on the editorial board of many scientific journals. He is a member of many professional societies, including the Prostate Conditions Education Council, the Society for Minimally Invasive Therapy, the New York State Urological Society, the American Association of Clinical Urologists, and the American Urologic Association. Dr. Stone has participated in approximately 25 research studies on prostate cancer and has authored more than 500 articles, abstracts, and book chapters, primarily on prostate cancer. He invented the real-time technique for prostate brachytherapy in 1990 and has trained more than 5,000 physicians worldwide through his company ProSeed. His most recent company, Viomerse, creates synthetic body parts (phantoms) for surgical training and has recently released an extended reality remote training platform.
